About PTC Therapeutics
PTC Therapeutics is a company based in South Plainfield (United States) founded in 1998. PTC Therapeutics has raised $248.1 million across 23 funding rounds from investors including Amgen, Novartis and Credit Suisse. The company has 939 employees as of December 31, 2024. PTC Therapeutics has completed 2 acquisitions, including Agilis Biotherapeutics and Censa Pharmaceuticals. PTC Therapeutics offers products and services including SMA Treatments, DMD Treatments, and PKU Treatments. PTC Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics and Biogen, among others.
- Headquarter South Plainfield, United States
- Employees 939 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ptc Therapeutics, Inc.
-
Annual Revenue
$806.78 M (USD)-13.97as on Dec 31, 2024
-
Net Profit
-$363.3 M (USD)42.02as on Dec 31, 2024
-
EBITDA
-$71.08 M (USD)36.99as on Dec 31, 2024
-
Total Equity Funding
$248.1 M (USD)
in 23 rounds
-
Latest Funding Round
$35.9 M (USD), Post-IPO
May 16, 2023
-
Investors
Amgen
& 23 more
-
Employee Count
939
as on Dec 31, 2024
-
Investments & Acquisitions
Agilis Biotherapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of PTC Therapeutics
PTC Therapeutics is a publicly listed company on the NASDAQ with ticker symbol PTCT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of PTC Therapeutics
PTC Therapeutics offers a comprehensive portfolio of products and services, including SMA Treatments, DMD Treatments, and PKU Treatments.
Medications for spinal muscular atrophy to enhance motor function.
Therapies for Duchenne muscular dystrophy to slow progression.
Solutions for phenylketonuria to manage metabolic issues.
People of PTC Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
63 people
Software Development Team
40 people
Finance and Accounting
26 people
Operations Team
26 people
Product Management Team
13 people
Regional Team
11 people
Legal and Compliance
9 people
Senior Team
9 people
Unlock access to complete
Funding Insights of PTC Therapeutics
PTC Therapeutics has successfully raised a total of $248.1M across 23 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35.9 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PTC Therapeutics
PTC Therapeutics has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Novartis and Credit Suisse.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital is directed toward healthcare companies by Longwood Fund.
|
Locked | Locked | Locked |
Investor details for PTC Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PTC Therapeutics
PTC Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Agilis Biotherapeutics and Censa Pharmaceuticals.
Investment portfolio details for PTC Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Drugs for Tetrahydrobiopterin deficiency and rare CNS disorders are developed.
|
Locked | Locked | 2015 | Locked | |
|
Gene therapy platform for rare monogenic CNS diseases is developed.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for PTC Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - PTC Therapeutics
Detailed financials for PTC Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ptc Therapeutics Comparisons
Peer comparison for PTC Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PTC Therapeutics
PTC Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics and Biogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
Detailed competitors of PTC Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ptc Therapeutics
Complete news archive for PTC Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PTC Therapeutics
PTC Therapeutics was founded in 1998 and raised its 1st funding round 3 years after it was founded.
PTC Therapeutics is headquartered in South Plainfield, United States. It is registered at South Plainfield, New Jersey, United States.
PTC Therapeutics is a funded company, having raised a total of $248.1M across 23 funding rounds to date.
As of Dec 31, 2024, the latest employee count at PTC Therapeutics is 939.
Annual revenue of PTC Therapeutics is $806.78M as on Dec 31, 2024.
PTC Therapeutics was founded in 1998 and is headquartered in South Plainfield, United States. Focus is placed on the development of small molecule drugs targeting rare diseases, with operations centered in the biotechnology sector. The lead product, Ataluren, is administered orally to address cystic fibrosis and Duchenne muscular dystrophy linked to nonsense mutations. Additional efforts are directed toward anticancer and antibacterial therapeutics.
PTC Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Spark Therapeutics.
PTC Therapeutics offers SMA Treatments, DMD Treatments, and PKU Treatments.
Yes, PTC Therapeutics is publicly traded on NASDAQ under the ticker symbol PTCT.
PTC Therapeutics has made 2 acquisitions, including Agilis Biotherapeutics, and Censa Pharmaceuticals.
PTC Therapeutics has 24 investors. Key investors include Amgen, Novartis, Credit Suisse, Manulife, and HHS.
The ticker symbol of PTC Therapeutics is PTCT on NASDAQ.